drugset / Trial / NCT06822049
Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)
Phase 2/3
Active not recruiting
200 enrolled
State University of New York at Buffalo
Abramson Cancer Center at Penn Medicine · collabMedical University of South Carolina · collabNational Center for Advancing Translational Sciences (NCATS) · collabUniversity of Alabama at Birmingham · collabUniversity of Pennsylvania · collabWake Forest University Health Sciences · collab
RandomizedParallel-groupOpen-labelOther
Summary
The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.
Timeline
- Start
- 2025-03-10
- Primary completion
- 2026-07-31
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Nicotine | Unknown | — | Oral |
Indications
No indication recorded.